RT Journal Article
SR Electronic
T1 The emergence, spread and vanishing of a French SARS-CoV-2 variant exemplifies the fate of RNA virus epidemics and obeys the Black Queen rule
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.04.22268715
DO 10.1101/2022.01.04.22268715
A1 Colson, Philippe
A1 Gautret, Philippe
A1 Delerce, Jeremy
A1 Chaudet, Hervé
A1 Pontarotti, Pierre
A1 Forterre, Patrick
A1 Tola, Raphael
A1 Bedotto, Marielle
A1 Delorme, Léa
A1 Levasseur, Anthony
A1 Lagier, Jean-Christophe
A1 Million, Matthieu
A1 Yahi, Nouara
A1 Fantini, Jacques
A1 La Scola, Bernard
A1 Fournier, Pierre-Edouard
A1 Raoult, Didier
YR 2022
UL http://medrxiv.org/content/early/2022/01/08/2022.01.04.22268715.abstract
AB The nature and dynamics of mutations associated with the emergence, spread and vanishing of SARS-CoV-2 variants causing successive waves are complex1-5. We determined the kinetics of the most common French variant (“Marseille-4”) for 10 months since its onset in July 20205. Here, we analysed and classified into subvariants and lineages 7,453 genomes obtained by next-generation sequencing. We identified two subvariants, Marseille-4A, which contains 22 different lineages of at least 50 genomes, and Marseille-4B. Their average lifetime was 4.1±1.4 months, during which 4.1±2.6 mutations accumulated. Growth rate was 0.079±0.045, varying from 0.010 to 0.173. All the lineages exhibited a “gamma” distribution. Several beneficial mutations at unpredicted sites initiated a new outbreak, while the accumulation of other mutations resulted in more viral heterogenicity, increased diversity and vanishing of the lineages. Marseille-4B emerged when the other Marseille-4 lineages vanished. Its ORF8 gene was knocked out by a stop codon, as reported in several mink lineages and in the alpha variant. This subvariant was associated with increased hospitalization and death rates, suggesting that ORF8 is a nonvirulence gene. We speculate that the observed heterogenicity of a lineage may predict the end of the outbreak.Competing Interest StatementD.R. is a scientific board member of Eurofins company, a founder of a microbial culture company (Culture Top), and was a consultant for Hitachi High-Technologies Corporation, Tokyo, Japan from 2018 to 2020. All other authors do not have any competing interest to declare. Funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.Funding StatementFrench Government under the Investments for the Future program managed by the National Agency for Research (ANR), no. Mediterranee-Infection 10-IAHU-03, and the Emergen Consortium (https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/consortium-emergen); Region Provence Alpes Cote d Azur and European funding FEDER PRIMMI (Fonds Europeen de Developpement Regional-Plateformes de Recherche et d'Innovation Mutualisees Mediterranee Infection), no. FEDER PA 0000320 PRIMMI.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study has been approved by the ethics committee of University Hospital Institute (IHU) Mediterranee Infection (No. 2020-016-3).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset generated and analyzed during the current study are available in the GISAID database (https://www.gisaid.org/).